Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
15. Mai 2024 18:00 ET
|
Vaccinex, Inc.
Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease in early June 2024. $8.2 million of new financing in Q1.
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
02. April 2024 08:30 ET
|
Vaccinex, Inc.
Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13. November 2023 08:00 ET
|
Vaccinex, Inc.
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
31. Oktober 2023 09:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
Vaccinex Announces Pricing of $9.6 Million Public Offering
28. September 2023 21:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
28. September 2023 08:00 ET
|
Vaccinex, Inc.
Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select...
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
26. September 2023 08:00 ET
|
Vaccinex, Inc.
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease...
Vaccinex, Inc. Announces Reverse Stock Split
22. September 2023 16:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
01. Juni 2023 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
15. Mai 2023 16:45 ET
|
Vaccinex, Inc.
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE...